💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dicyclomine

CHEMBL1123 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
309.5 g/mol
LogP
5.5
Phase
4

An anticholinergic medication used to treat irritable bowel syndrome and other functional gastrointestinal disorders by relaxing the smooth muscle of the gut and reducing painful intestinal spasms. It works by blocking muscarinic receptors in the digestive tract. Common side effects include dry mouth, blurred vision, urinary retention, and confusion, particularly in elderly patients.

Молекулярная масса

309,5000 g/mol

LogP

5,50

TPSA

29,50 Ų

Правило пяти Липинского

Соответствует

Механизм действия

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H35NO2

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
Вращаемые Связи

                        
8

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
An anticholinergic medication used to treat irritable bowel syndrome and other functional gastrointestinal disorders by relaxing the smooth muscle of the gut and reducing painful intestinal spasms. It works by blocking muscarinic receptors in the digestive tract. Common side effects include dry mouth, blurred vision, urinary retention, and confusion, particularly in elderly patients.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Dicyclomine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1123.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3042.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.